Kyntra Bio (NASDAQ:KYNB) Trading Down 1.3% – Here’s What Happened

Shares of Kyntra Bio Inc (NASDAQ:KYNB) were down 1.3% during trading on Monday . The stock traded as low as $7.02 and last traded at $7.08. Approximately 28,374 shares were traded during mid-day trading, a decline of 4% from the average daily volume of 29,707 shares. The stock had previously closed at $7.17.

Analyst Ratings Changes

Several analysts have commented on KYNB shares. HC Wainwright upgraded shares of Kyntra Bio to a “strong-buy” rating in a research note on Friday, February 27th. Zacks Research cut shares of Kyntra Bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 6th. Weiss Ratings started coverage on shares of Kyntra Bio in a research note on Wednesday, January 14th. They issued a “sell (d+)” rating on the stock. Finally, Wall Street Zen cut shares of Kyntra Bio from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kyntra Bio currently has a consensus rating of “Hold”.

Kyntra Bio Stock Performance

The stock’s 50-day simple moving average is $7.22. The firm has a market cap of $29.18 million, a price-to-earnings ratio of 0.16 and a beta of 0.90.

About Kyntra Bio

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in the United States, Europe, China, and Japan; and in Phase II/III development in China for anemia associated with myelodysplastic syndromes.